Women's Health March 5, 2026 0 Comments

This Surprising GLP-1 Drug Benefit Could Change Everything You Thought You Knew About Weight Loss—And No One’s Talking About It Yet!

Ever catch yourself wondering if the miracle drug you’re hearing about for weight loss and heart health might just moonlight as a secret weapon against migraines? Well, buckle up — because GLP-1 medications, those popular shots and pills you’ve probably heard buzzing around for diabetes and obesity, are now making waves in the migraine world. Imagine a world where a single treatment could potentially ease the pounding headaches for nearly 22,000 people studied — sounds like a punchline to a health joke, but it’s real talk. Researchers compared GLP-1 users to folks on topiramate, a tried-and-true migraine preventive, and the results? Intriguing enough to spark curiosity and a few hopeful glances from headache specialists. Now, before you start dreaming of a migraine-free life thanks to your diabetes or weight-loss med, remember — this isn’t a prescription pad moment yet. But still, this new link puts us on the edge of something exciting. Ready to dive into the details and see what the experts have to say? Let’s get into it. LEARN MORE

4 min read

New findings show a link between GLP-1 use and a lower risk of severe migraines.
Researchers looked at nearly 22,000 patients and compared the hospital records of those on GLP-1 drugs with those of a preventive migraine drug to see which group went to the hospital less for migraine-related issues.
The results are promising, but more research is needed before providers start prescribing GLP-1s specifically to help with chronic migraines.

GLP-1 drugs have been linked to everything from weight loss to a lower risk of developing cardiovascular disease, with new benefits coming out all the time. But while the latest potential perk seems a little random, it’s one plenty of people can get behind.

Now, new research that will be presented at the American Academy of Neurology’s annual meeting in April links these popular drugs to a lower risk of severe migraine pain. The findings are fascinating and raise a lot of questions about whether GLP-1s like Ozempic and Wegovy will be prescribed to help migraine sufferers in the future.

Here’s what the study found, plus what headache specialists want you to keep in mind.

Meet the experts: Dharti Dua, MD, neurologist and clinical assistant professor at The Ohio State University Wexner Medical Center and College of Medicine; Suraj Malhan, DO, headache and facial pain neurologist at RWJBarnabas Health, Monmouth Medical Center; Hsiangkuo Yuan, MD, PhD, study co-author and clinical research director at Jefferson Headache Center; Medhat Mikhael, MD, pain management specialist at MemorialCare Orange Coast Medical Center in Fountain Valley, California

What did the study find?

For the study, researchers analyzed medical records of nearly 22,000 people who suffered from chronic migraines. (Migraines are considered chronic when someone has a headache on 15 or more days a month for at least three months.)

The researchers divided the participants into two groups: Those who started taking a GLP-1 medication for another condition (such as type 2 diabetes or obesity) within a year of being diagnosed with chronic migraines, and those who started taking topiramate (a prescription medication used to prevent migraine headaches) during the same period. People in the GLP-1 camp took a range of medications in this category, including semaglutide, liraglutide, and others.

The team then tracked the medical records of these patients over the following year, looking for things related to severe migraine headaches, such as emergency room visits, hospitalizations, nerve block procedures, and new prescriptions for medications used to prevent or stop migraines.

They discovered that 23.7% of people who started GLP-1 medications visited the emergency room over the next year, compared with 26.4% of those who started topiramate. People who took a GLP-1 were also about 10% less likely to visit the emergency room with migraine symptoms and about 13% less likely to undergo a nerve block procedure or to get a prescription for a triptan (a type of medication that stops migraines) compared to people who took topiramate.

Why might GLP-1s lower the risk of migraine?

It’s important to point out a few things first. One is that this study was observational, so it didn’t definitively find that GLP-1s lowered the risk of severe migraine pain—it just found a link. Another is that GLP-1s didn’t completely eliminate severe migraine pain, but the findings do suggest GLP-1s are associated with reduced migraine severity.

There’s no definitive answer for why yet, but the experts have a few theories. Migraine is a complex neurological disease that involves inflammation, changes in pain signaling, and a range of other complications, explains Suraj Malhan, DO, a headache and facial pain neurologist at RWJBarnabas Health, Monmouth Medical Center. “GLP-1 receptor agonists have been shown to have anti-inflammatory and neuroprotective effects, which could reduce migraine susceptibility,” he says.

Malhan also says there may be metabolic elements involved, too. “Migraine often overlaps with conditions like obesity, insulin resistance, and sleep apnea, and improving overall metabolic health can sometimes reduce migraine burden,” he says.

It’s also possible that people taking GLP-1s were doing other things that lowered their risk of severe migraines, says Dharti Dua, MD, neurologist and clinical assistant professor at The Ohio State University Wexner Medical Center and College of Medicine. Given the high cost of GLP-1s, the patients in that arm of the study may also have had greater access to resources (exercise programs, health coaches, and nutritionists), she says.

Dua also points out that losing weight is linked with a better mood, which can help reduce migraine severity and improve a person’s ability to cope with pain.

Will we see GLP-1s as a future migraine treatment?

That’s a stretch—for now, at least. These drugs have a few challenges, including their high cost, Dua points out. “Not all patients can afford these medications,” she says.

Still, don’t count this out entirely. “I wouldn’t say no because GLP-1s have been surprising to a lot of people and are promising to treat obesity, which is a risk factor for migraine,” says Medhat Mikhael, MD, pain management specialist at MemorialCare Orange Coast Medical Center in Fountain Valley, California. “However, GLP-1s need to be studied more and on a wider scale.”

Hsiangkuo Yuan, MD, PhD, study co-author and clinical research director at Jefferson Headache Center, agrees, noting that if someone already has obesity and struggles with migraines, taking a GLP-1 may help with both issues. “Weight reduction is already an important component of migraine management for patients with elevated BMI,” he says.

But Yuan says more work needs to be done before doctors will recommend GLP-1s for patients with chronic migraine. “No randomized, placebo-controlled trials have yet demonstrated efficacy specifically for migraine,” he says.

Korin Miller is a freelance writer specializing in general wellness, sexual health and relationships, and lifestyle trends, with work appearing in Men’s Health, Women’s Health, Self, Glamour, and more. She has a master’s degree from American University, lives by the beach, and hopes to own a teacup pig and taco truck one day.